Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

3.7K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
3.7K
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

2.7K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
2.7K
Ligand-gated Ion Channels01:19

Ligand-gated Ion Channels

13.9K
Ligand-gated ion channels are transmembrane proteins with a channel for ions to pass through and a binding site for a ligand. The channel opens only when a ligand attaches to the binding site.
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
13.9K
The Two-State Receptor Model01:29

The Two-State Receptor Model

3.0K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
3.0K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

4.6K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
4.6K
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

3.9K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Native architecture, allosteric modulation and gating mechanism of glycine-dependent NMDA receptors.

bioRxiv : the preprint server for biology·2026
Same author

UCM-A86 is a selective positive allosteric modulator of GluN1/GluN3 NMDA receptors.

bioRxiv : the preprint server for biology·2025
Same author

The thrombin receptor PAR1 orchestrates changes in lymphatic endothelial cell junction morphology to augment lymphatic drainage during lung injury.

Nature cardiovascular research·2025
Same author

Design of (<i>R</i>)-3-(5-Thienyl)carboxamido-2-aminopropanoic Acid Derivatives as Novel NMDA Receptor Glycine Site Agonists: Variation in Molecular Geometry to Improve Potency and Augment GluN2 Subunit-Specific Activity.

Journal of medicinal chemistry·2025
Same author

Evaluation of allosteric NMDA receptor modulation by GluN2A-selective antagonists using pharmacological equilibrium modeling.

Molecular pharmacology·2024
Same author

Allosteric modulation of GluN1/GluN3 NMDA receptors by GluN1-selective competitive antagonists.

The Journal of general physiology·2023
Same journal

On the mechanism of hypomagnesemia with treatment-resistant seizures caused by variants of the Na+,K+-ATPase α1 subunit (ATP1A1).

The Journal of general physiology·2026
Same journal

Label-free real-time imaging of mitochondrial matrix volume changes and permeability transition in living cells.

The Journal of general physiology·2026
Same journal

Differential regulation of β1-dependent voltage shifts and kinetic modulation by an extracellular glutamate in NaV1.6 VSDIV.

The Journal of general physiology·2026
Same journal

Mechanistic insights into DCPIB inhibition of VRAC: Electrostatic control and binding plasticity.

The Journal of general physiology·2026
Same journal

An epilepsy-associated KV3.1 potassium channel variant acts via dominant-positive effect.

The Journal of general physiology·2026
Same journal

Regulation of olfactory chloride and cyclic nucleotide-gated channels by cholesterol.

The Journal of general physiology·2026
See all related articles

Related Experiment Video

Updated: Jan 9, 2026

A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate
04:48

A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate

Published on: July 10, 2018

9.7K

Novel binding mode for negative allosteric NMDA receptor modulators.

James S Lotti1,2, Jed T Syrenne1,2, Avery J Benton1,2

  • 1Center for Structural and Functional Neuroscience, Division of Biological and Biomedical Sciences, University of Montana, Missoula, MT, USA.

The Journal of General Physiology
|December 3, 2025
PubMed
Summary
This summary is machine-generated.

A novel compound, UCM-101, fully inhibits NMDA receptor activity by binding to a unique site. This discovery offers new therapeutic possibilities for brain disorders linked to aberrant NMDA receptor signaling.

More Related Videos

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.2K
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.4K

Related Experiment Videos

Last Updated: Jan 9, 2026

A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate
04:48

A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate

Published on: July 10, 2018

9.7K
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.2K
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.4K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Structural Biology

Background:

  • NMDA receptors are crucial for brain function, mediating neurotransmission and plasticity.
  • Dysregulated NMDA receptor signaling is linked to various neurological and psychiatric disorders.
  • Developing selective modulators is key for therapeutic intervention.

Purpose of the Study:

  • To elucidate the binding site and mechanism of action of UCM-101, a novel negative NMDA receptor modulator.
  • To characterize the subunit selectivity and inhibitory potency of UCM-101.
  • To provide structural insights into NMDA receptor modulation.

Main Methods:

  • Electrophysiology in mouse hippocampal slices to measure NMDA receptor currents.
  • High-resolution crystal structure determination of the GluN1/2A agonist binding domain.
  • Biochemical assays to determine binding affinity and IC50 values.

Main Results:

  • UCM-101 fully inhibits NMDA receptor-mediated currents in hippocampal neurons.
  • UCM-101 exhibits higher binding affinity for GluN1/2A over GluN1/2B receptors.
  • Crystal structure reveals a novel binding mode, distinct from other antagonists, enabling allosteric inhibition.

Conclusions:

  • UCM-101 represents a novel class of NMDA receptor negative allosteric modulators.
  • Its unique binding site and subunit selectivity offer therapeutic potential for brain disorders.
  • Structural and mechanistic insights pave the way for developing targeted NMDA receptor therapeutics.